KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...
Case Western Reserve University researchers have taken a dramatic step forward in the fight against cancer—all by starting at the very beginning. Scientists led by School of Medicine Professor Mark W.
Morning Overview on MSN
How gene mutations disrupt cell growth and trigger cancer?
Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells to multiply without restraint. Decades of research have traced this process ...
TT125-802 targets transcriptional pathways in NSCLC with EGFR or KRAS-G12C mutations, addressing resistance to current therapies. The therapy has shown promising single-agent activity and a favorable ...
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors.
Molecular profiling of neoadjuvant immunochemotherapy and identification of residual cancer cells in pCR NSCLC: A single-cell analysis of CTONG 1804 clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results